Physician profile
Jon Allison
NPI 1558559682
$4,210.87
in general payments reported to CMS, 2019-2025
11 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $331 · 2021: $345 · 2022: $612 · 2023: $846 · 2024: $1,159 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,348.65 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $828.20 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $643.59 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $399.00 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $353.69 | 2019-2024 | Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.38 | 2021-2025 | Caplyta |
| Indivior INC. | $136.92 | 2019-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $86.40 | 2019-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $54.66 | 2024-2025 | Cobenfy |
| Abbvie INC. | $36.83 | 2023-2024 | Vraylar |
| Eisai INC. | $20.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.